Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s
The ARCT stock price is -20.15% off its 52-week high price of $66.24 and 84.56% above the 52-week … MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Do Insiders Own Lots Of Shares In Arcturus Therapeutics Ltd. ? View our full suite of financial calendars and market data tables, all for free. Sporting 0.75% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Friday, Oct 16 when the ARCT stock price touched $57.47- or saw a rise of 4.07%. This investing legend has flipped options trading upside down... making money on 85% of his trades. Roth Capital assumed coverage on Arcturus Therapeutics in a report on Thursday, July 30th. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Commerce Policy |
Arcturus Therapeutics Appoints Andrew Sassine as Interim Chief Financial Officer, Arcturus Therapeutics to Present at Three Investor Conferences in September, Arcturus Therapeutics Issues Open Letter to Shareholders, Arcturus Therapeutics Initiates Lawsuit Against Joseph E. Payne to Protect the Interests of Arcturus Shareholders, Arcturus Therapeutics Announces Extraordinary General Meeting of Shareholders, Arcturus Therapeutics Calls on Proposed Director Nominees to Respond to Constructive Board Outreach, Arcturus Therapeutics Comments on Amended 13D Filing, Wired News – Arcturus Therapeutics Appoints Dr. Christine Esau as Vice President of R&D, Arcturus Therapeutics Appoints Dr. Christine Esau as Vice President of Research and Development, Other Events; Financial Statements and Exhibits, Entry into a Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibits, Results of Operations and Financial Condition; Financial Statements and Exhibits, Entry into a Material Definitive Agreement; Financial Statements and Exhibits, Regulation FD Disclosure; Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders, Unregistered Sales of Equity Securities; Regulation FD Disclosure; Financial Statements and Exhibits, CEO Joseph Payne on Q2 2019 Results - Earnings Call Transcript. They issued a "buy" rating and a $77.00 target price on the stock. Its pipeline include LUNAR-OTC and LUNAR CF. Du kan ændre dine valg når som helst i Dine kontrolfunktioner til beskyttelse af private oplysninger. NasdaqGM - NasdaqGM Real Time Price. Made In NYC |
Since then, ARCT shares have increased by 294.0% and is now trading at $51.57. When Will Arcturus Therapeutics Holdings Inc. Track performance, allocation, dividends, and risks, Annotate, download XLSX & look up similar tables, Filter, compare, and track coins & tokens, Stocks and cryptocurrency portfolio tracker, Stock-Specific Ideas for the Post-Fed Era of Investing. Please log in to your account or sign up in order to add this asset to your watchlist. This investing legend has flipped options trading upside down... making money on 85% of his trades. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. The expected earnings per share for the stock is -$0.48. Why Earnings Season Could Be Great for Arcturus Therapeutics ? Vi og vores partnere opbevarer og/eller har adgang til oplysninger om din enhed via brugen af cookies og lignende teknologier for at vise personligt tilpassede annoncer og personligt tilpasset indhold, til måling af annoncer og indholds effektivitet, til indsigt om målgrupper samt produktudvikling. Arcturus Therapeutics Ltd. ARCT 55.13 0.41 (0.75%). Is Arcturus Therapeutics Ltd A Financially Sound Company? Dividend). Arcturus Therapeutics Holdings Inc. Q1 2020 Earnings Call Transcript, Arcturus Therapeutics and Catalent Announce Partnership to Manufacture mRNA-Based COVID-19 Vaccine - Yahoo Finance, Arcturus Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - Yahoo Finance, Arcturus Therapeutics Announces Proposed Public Offering of Common Stock - Yahoo Finance, Arcturus Therapeutics Holdings Inc. Analysts Are Pretty Bullish On The Stock After Recent Results, Arcturus Therapeutics Reports Q4 Loss, Lags Revenue Estimates, Coronavirus Vaccine Makes This Stock a “Strong Buy”. Arcturus Therapeutics Holdings, Inc. engages in the research and development of medical applications for the nucleic acid-focused technology. Receive a free world-class investing education from MarketBeat. The Arcturus Therapeutics Holdings Share Price Has Gained 114%, So Why Not Pay It Some Attention? Sign Up. The shares were sold at an average price of $42.83, for a total transaction of $428,300.00. Source: FactSet. Follow My #1 Rule Instead. Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) COO Pad Chivukula sold 10,000 shares of Arcturus Therapeutics stock in a transaction that occurred on Thursday, October 1st. Arcturus Therapeutics Holdings Inc. Q1 2020 Earnings Call Transcript Monday, 4 May 2020 yahoo . Arcturus Therapeutics' stock was trading at $13.09 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Investors should focus on Arcturus' progress with its COVID-19 vaccine program rather than the biotech stock 's wild gyrations, which could be -- and arguably will be -- … Yahoo er en del af Verizon Media. Du kan give Verizon Media og vores partnere lov til at behandle dine personlige data ved at vælge 'Jeg accepterer'. Arcturus Therapeutics Holdings Inc. (ARCT) Add to watchlist. We have proprietary technologies, validating partnerships, and an experienced team with deep expertise in delivery and RNA-based therapeutics Post-Market 1.87 (3.39%) Do the numbers hold clues to what lies ahead for the stock? Start Your Risk-Free Trial Subscription Here, Lennox International Inc (NYSE:LII) Is On Breakout Watch After Q3 Earnings, Is Sorrento Therapeutics (NASDAQ:SRNE) More Than Just A COVID-19 Play, Nokia (NYSE: NOK) Stock is a Bargain Pure Play on 5G Rollout, Chipotle (NYSE: CMG) is a Buy Ahead of Earnings, 3 Big Earnings Reports to Watch in the Coming Weeks, Where Next For Shares of Zoom Video (NASDAQ: ZM), 3 Stocks to Buy with Recent Dividend Increases, 3 Beaten Down Stocks On The Cusp Of A Major Reversal, V.F. Former Wall Street whiz kid says there’s one small company at the epicenter of the $3 TRILLION electric car boom… and very few people are paying attention to it right now. The firm develops RNA therapeutics which focuses on the treatment of liver and respiratory diseases. View which … The company was founded in 2013 and is headquartered in San Diego, CA. Arcturus Therapeutics Ltd . Arcturus Therapeutics Expected to Beat Earnings Estimates: Should You Buy? Arcturus Therapeutics Ltd 55.13 0.41 (0.75%) Watch. Its pipeline include LUNAR-OTC and LUNAR CF. Get daily stock ideas top-performing Wall Street analysts. Sunday, 10 May 2020 fool. Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) went up by 2.99% from its latest closing price compared to the recent 1-year high of $66.24. It could help you make as much as $185 a day on average… in as little as 9 minutes a weekdocument.write('
'); View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. The Investor Relations website contains information about Arcturus Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
Dawn French Husband Mark Bignell
Who Are Chloe Coleman Parents
Goodnight Moon Print
Do I Have Endometriosis Or Pcos Quiz
San Antonio Spurs Coach